Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT05669820

Antisecretory Factor Glioblastoma Phase 2

Conditions: Glioblastoma

Sex: All

Ages: 18 Years – 75 Years

Phase: PHASE2, PHASE3

Enrollment: 300

Sponsor: Peter Siesjö

Location: Sweden

Summary

This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis

Eligibility Criteria

Inclusion Criteria:Pathology verified glioblastoma or astrocytoma grade 4Age 18-75 yearsSurgical treatment-resection.Scheduled concomitant radiochemotherapy, or only chemotherapy.Informed consentExclusion Criteria:No informed consentEgg yolk allergyOnly surgical biopsyOnly radiotherapy

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05669820). StuddyBuddy aggregates publicly available trial information.